Purevax RCPCh FeLV

RSS

vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia, feline leukeamia and feline Chlamydophila infections

Authorised
This medicine is authorised for use in the European Union.

Overview

Purevax RCPCh FeLV is a veterinary vaccine that is used to vaccinate cats from the age of 8 weeks against:

  • feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus),
  • feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus),
  • feline chlamydiosis (a flu-like illness caused by the bacterium C. felis),
  • feline panleucopenia (a serious illness causing bloody diarrhoea caused by a parvovirus),
  • feline leukaemia (an illness affecting the immune system caused by a retrovirus, feline leukaemia virus).

The vaccine helps to reduce the symptoms of the diseases. It can also prevent death due to panleucopenia and prevent FeLV from remaining in the blood.

Purevax RCPCh FeLV contains:

  • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain),
  • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains),
  • attenuated Chlamydophila felis (905 strain),
  • attenuated feline panleucopenia virus (PLI IV),
  • feline leukaemia virus (FeLV) recombinant canarypox virus (vCP97).
This EPAR was last updated on 08/03/2021

Authorisation details

Product details
Name
Purevax RCPCh FeLV
Agency product number
EMEA/V/C/000085
Active substance
  • attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)
  • inactivated feline calicivirosis antigens (FCV 431 and G1 strains)
  • attenuated feline panleucopenia virus (PLI IV)
  • FeLV recombinant canarypox virus (vCP97)
  • attenuated Chlamydophila felis (905 strain)
International non-proprietary name (INN) or common name
vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia, feline leukeamia and feline Chlamydophila infections
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI06AJ05
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Revision
14
Date of issue of marketing authorisation valid throughout the European Union
23/02/2005
Contact address

Binger Strasse 173
55216 Ingelheim am Rhein
Germany

Product information

14/10/2020 Purevax RCPCh FeLV - EMEA/V/C/000085 - WS/1733/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Active immunisation of cats aged 8 weeks and older:

  • against feline viral rhinotracheitis to reduce clinical signs;
  • against calicivirus infection to reduce clinical signs;
  • against Chlamydophila felis infection to reduce clinical signs;
  • against feline panleucopenia to prevent mortality and clinical signs;
  • against leukaemia to prevent persistent viraemia and clinical signs of the related disease.

Onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.

The duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Assessment history

News

How useful was this page?

Add your rating